ACTICOR BIOTECH EO 1
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
ACTICOR BIOTECH EO 1 (7V7) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ACTICOR BIOTECH EO 1 (7V7) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ACTICOR BIOTECH EO 1 - Net Assets Trend (None–None)
This chart illustrates how ACTICOR BIOTECH EO 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACTICOR BIOTECH EO 1 (None–None)
The table below shows the annual net assets of ACTICOR BIOTECH EO 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ACTICOR BIOTECH EO 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ACTICOR BIOTECH EO 1 Competitors by Market Cap
The table below lists competitors of ACTICOR BIOTECH EO 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pavna Industries Limited
NSE:PAVNAIND
|
$6.36 Million |
|
Alpha Modus Holdings, Inc
NASDAQ:AMOD
|
$6.37 Million |
|
MODEL
ST:MODEL
|
$6.37 Million |
|
DURUKAN SEKERLEME
IS:DURKN
|
$6.37 Million |
|
LZ Technology Holdings Limited Class B Ordinary Shares
NASDAQ:LZMH
|
$6.36 Million |
|
I.E.S Holdings Ltd
TA:IES
|
$6.36 Million |
|
Mida Assets Public Company Limited
BK:MIDA
|
$6.36 Million |
|
AMERICAN POTASH CORP.
F:2P3
|
$6.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACTICOR BIOTECH EO 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ACTICOR BIOTECH EO 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ACTICOR BIOTECH EO 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ACTICOR BIOTECH EO 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACTICOR BIOTECH EO 1 (7V7) | €- | N/A | N/A | $6.36 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |